Steven Chmura, MD
To determine the recommended SBRT dose for each of the metastatic locations being treated given the individual and overlapping fields when multiple metastases are treated with SBRT in a national clinical trials network setting
Oligometastases arising from the breast, lung or prostate; oligometastases defined as ≤ 4 distinct metastases visualized on standard imaging studies; all metastases not resected must be amenable to SBRT; local and regional disease treated per standard of care with no evidence of progression
Activated August 4, 2014
The protocol and related documents are available at NRG-BR001
RT Credentialing and Treatment Planning Materials
to visit the IROC website for extensive information about benchmark case planning, credentialing, and treatment planning guidelines.